Should I Avoid Bellicum Pharmaceuticals Inc (BLCM)?
As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade.
Bellicum Pharmaceuticals Inc (BLCM)
Get Email AlertsSector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Ikarian Capital Neil Shahrestani | 523,348 | $1,131 | +6% | 0.14% |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 249,123 | $538 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.00 | 5,000 | Officer, Director | 5,000 | 2020-03-17 | Filing | |
| $1.25 | 40,000 | Officer, Director | 66,561 | 2019-09-10 | Filing | |
| $1.23 | 8,000 | Officer | 18,294 | 2019-08-29 | Filing | |
| $0.99 | 20,000 | Officer, Director | 26,561 | 2019-08-21 | Filing | |
| $4.56 | 10,000 | Director | 10,000 | 2018-11-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.04 | 10,000 | Officer | 89,939 | 2018-09-04 | Filing | |
| $7.63 | 40,000 | Officer | 99,939 | 2018-07-18 | Filing | |
| $7.97 | 6,206 | Officer | 26,548 | 2018-05-25 | Filing | |
| $7.91 | 4,136 | Large Shareholder | 58,131 | 2018-01-19 | Filing | |
| $7.91 | 265,708 | Large Shareholder | 3,734,776 | 2018-01-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 364,720 | $788 | 0% | |
| 2. | 239,762 | $518 | 0.06% | |
| 3. | 75,522 | $163 | 0% | |
| 4. | 72,925 | $157 | 0% | |
| 5. | 56,950 | $123 | 0% |
News See All
Is Bellicum Pharmaceuticals Inc (BLCM) A Good Stock To Buy?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities...
Here is What Hedge Funds Think About Bellicum Pharmaceuticals Inc (BLCM)
In this article you are going to find out whether hedge funds think Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) is a good investment right now.
Hedge Funds Are Betting On Bellicum Pharmaceuticals Inc (BLCM)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.
13G Filing: Baker Bros. Advisors and Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)
You can access the original SEC filing by clicking here.
13D Filing: Baker Bros. Advisors and Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)
You can access the original SEC filing by clicking here.
13D Filing: Baker Bros. Advisors Owns 18% of Bellicum Pharmaceuticals, Inc (BLCM)
At Insider Monkey, we closely monitor the moves made by activist investors. Their targets are often undervalued stocks with firm foundations that for one reason or another have failed to execute.
A Look At Three Activist Moves By Several Elite Hedge Funds
According to the Schulte, Roth & Zabel’s Activist Investing 2015 Annual Review, 344 companies were targeted by activist investors in 2014, as compared with 291 recorded a year earlier.
Hedge Fund Sentiment Is Stagnant On Bellicum Pharmaceuticals Inc (BLCM)
A market correction in the third quarter, spurred by a number of global macroeconomic concerns ended up having a negative impact on the markets and many hedge funds as a result.
Gilead Sciences (GILD), AstraZeneca (AZN), Bellicum Pharmaceuticals (BLCM): Redmile Group’s Top New Picks
Jeremy Green’s Redmile Group entered several new positions last quarter, as revealed by the 13F Form it filed with the U.S. Securities and Exchange Commission in February.
Billionaire Hedge Funds
